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Favorable Results of Concomitant Tacrolimus
and Sirolimus Therapy in Taiwanese Renal
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Background/Purpose: Combined therapy of sirolimus and cyclosporine has been found to exacerbate 
cyclosporine-related nephrotoxicity and to imperil graft renal function. We hypothesized that tacrolimus
could bring about better renal function than cyclosporine when used in combination with sirolimus and
corticosteroids for de novo renal transplantation.
Methods: A two-arm randomized study was conducted to test the hypothesis. Patients who gave written
informed consent and received renal transplantation were randomized to take sirolimus in combination
with either tacrolimus or cyclosporine. The primary endpoint of this study was renal function, and the sec-
ondary endpoints were acute rejection, graft and patient survival, metabolic side effects and infectious
complications.
Results: A total of 41 Taiwanese renal transplant patients were randomized to receive cyclosporine (CsA
group, n = 20) or tacrolimus (TAC group, n = 21) in combination with sirolimus and corticosteroids. 
The average estimated glomerular filtration rate (eGFR) was 52.77 ± 3.86 mL per minute for the TAC group
at 6 months, and 46.42 ± 3.95 mL per minute for the CsA group (p > 0.05). At 12 months, the average
eGFR was 52.04 ± 4.38 mL per minute for the TAC group, and 46.79 ± 4.38 mL per minute for the CsA
group (p > 0.05). The biopsy-proven acute rejection rate of the TAC group was 4.76% (1/21), and that of
the CsA group was 5.00% (1/20) at 12 months. The 12-month graft survival rates for the TAC and CsA
groups were 100% and 90% (p = 0.142), respectively.
Conclusion: Our study demonstrated that concomitant tacrolimus and sirolimus therapy resulted in a 
favorable outcome in Taiwanese renal transplant patients at 12 months. Large-scale clinical trials will be
needed to further address the issue of which calcineurin inhibitor, cyclosporine or tacrolimus, provides better
renal function and graft survival for renal transplant patients. [J Formos Med Assoc 2008;107(7):533–539]
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ORIGINAL ARTICLE
Sirolimus (SRL, rapamycin), a macrocyclic lac-
tone that binds FKBP 12 and inhibits the 
mammalian target of rapamycin-mediated signal-
transduction pathway, was found to produce an
immunosuppressive synergism with cyclospor-
ine, which inhibits calcineurin and the associ-
ated signal transduction of T-cell receptors.1 The
US and global trials on combined sirolimus and 
cyclosporine (CsA) regimens showed that patients
with combined sirolimus and cyclosporine ther-
apy had markedly reduced acute rejection rates.2,3
Interestingly, in these two studies, the mean se-
rum creatinine levels of the sirolimus groups at 
6 months were significantly higher than those of
the azathioprine group and the placebo group.2,3
A significant pharmacokinetic interaction between
sirolimus and cyclosporine was observed, and
sirolimus actually augmented the nephrotoxicity
of cyclosporine even at low concentrations.4
While tacrolimus (TAC), also a calcineurin in-
hibitor (CNI), was found to have less pharmaco-
kinetic interaction with sirolimus, tacrolimus
could be a better choice to produce immunosup-
pressive synergism with sirolimus.5 Animal mod-
els have demonstrated that sirolimus could
prolong allograft survival without adverse effects
on glomerular function or on interstitial fibro-
sis.6 Combined tacrolimus and sirolimus therapy,
therefore, could provide adequate immunosup-
pressive effects without overt nephrotoxicity, which
could occur when sirolimus was combined with
cyclosporine. We hypothesized that tacrolimus
could result in better renal function than cy-
closporine when used in combination with
sirolimus and corticosteroids for de novo renal
transplantation. A prospective two-arm random-
ized study was accordingly conducted to test the
hypothesis.
Methods
A prospective two-arm randomized study was
undertaken to test the hypothesis that tacrolimus
could result in better renal function than cyclo-
sporine when used in combination with sirolimus
for de novo renal transplantation. The institutional
review board approved the protocol, and patients
gave written informed consent preoperatively to
be enrolled. Adult patients with their first renal
transplant were blindly randomized by a random-
ization sequence to receive either cyclosporine
(Neoral; Novartis, Basel, Switzerland) (CsA group)
or tacrolimus (Prograf; Fujisawa Healthcare,
Deerfield, IL, USA) (TAC group) in combination
with sirolimus (Rapamune; Wyeth-Ayerst, Radnor,
PA, USA) and corticosteroids. Patients with chron-
ic hepatitis B or C viral infection or any other active
infection were excluded.
Patients who were randomized to the CsA
group received cyclosporine at an initial dose of
3 mg/kg twice daily. The trough levels were main-
tained at 100–200 ng/mL. In the TAC group, the
initial dose of tacrolimus was 0.05 mg/kg twice
daily, and the trough levels were kept at 4–8 ng/
mL. Additionally, sirolimus was given to all pa-
tients at a loading dose of 6 mg on the day after
transplantation, and then at 2 mg daily starting 
2 days after transplantation. The trough levels 
of sirolimus were kept at 4–8 ng/mL. Cortico-
steroids were given as usual. Every patient took
valganciclovir (Valcyte; Roche, Nutley, NJ, USA)
at a dose of 450 mg/day for 3 months to prevent
cytomegalovirus disease. Valganciclovir was dis-
continued if significant bone marrow suppression
occurred.
The graft function was monitored by regular
checks of serum creatinine. The Cockcroft-Gault
formula was used for calculation of estimated
glomerular filtration rate (eGFR), with a correc-
tion factor of 0.85 in women. Acute rejection was
suspected when an increase of over 30% in
serum creatinine was noted. Graft biopsy was
performed in every patient with suspected acute
rejection. Post-transplant diabetes was defined as
insulin usage for more than 30 days or regular
use of hypoglycemic agents in recipients without
a history of diabetes prior to transplant. Lipid
profiles were regularly checked, and cholesterol
levels above 240 ng/mL or triglyceride levels
more than 200 ng/mL were considered to indi-
cate dyslipidemia. The primary endpoint was 
estimated renal function, and the secondary 
endpoints were biopsy-proven acute rejection,
graft survival, patient survival, metabolic side ef-
fects and infectious complications. Statistical
analyses were performed using NCSS 2000 soft-
ware (NCSS, Kaysville, UT, USA) for Windows.
All values were expressed as mean ± standard 
deviation (SD).
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Results
From March 2002 to February 2004, a total of 41
Taiwanese renal transplant recipients were ran-
domized to receive cyclosporine (CsA group,
n = 20) or tacrolimus (TAC group, n = 21) in com-
bination with sirolimus and corticosteroids for
de novo immunosuppressive therapy. The patients
were from 22 to 62 years old. The average age of
the CsA group was 40.2 ± 2.4 years, and that of
the TAC group was 42.7 ± 2.3. More female pa-
tients than males were recruited in both groups;
13 of the 20 patients in the CsA group and 16 of
the 21 patients in the TAC group were female. 
In the CsA group, seven of the 20 transplants
were from live donation, while it was eight of 21
in the TAC group. The average mismatch between
donor and recipient human lymphocyte antigens
was 2.8 ± 0.3 for the CsA group and 3.3 ± 0.3 for
the TAC group. The incidence of delayed graft
function for the CsA and TAC groups were 20.0%
and 14.3%, respectively. The demographic char-
acteristics and 12-month outcome of both groups
are summarized in the Table.
During the study period, three patients of the
CsA group stopped taking cyclosporine and were
converted to tacrolimus individually because of
hirsutism, rapidly progressing glomerulonephri-
tis and hemolytic uremic syndrome. The average
dose and trough level of cyclosporine were
123.33 ± 33.36 mg/day and 86.38 ± 36.72 ng/mL
at 6 months, respectively. At 12 months, the aver-
age dose of cyclosporine was 93.75 ± 41.46 mg/
day, and the average trough level was 50.55 ±
26.04 ng/mL. All the patients in the TAC group
were maintained on tacrolimus therapy for the
12-month follow-up period. The average dose and
trough level of tacrolimus were 6.00 ± 3.03 mg/
day and 5.97 ± 2.01 ng/mL at 6 months, respec-
tively. The average dose of tacrolimus was 5.03 ±
3.16 mg/day, and the average trough level was
4.90 ± 1.94 ng/mL at 12 months. The average dose
and trough blood level of tacrolimus and cyclo-
sporine are shown in Figure 1. As for sirolimus,
the average daily doses for the TAC group were
1.47 ± 0.56 mg/day and 1.53 ± 0.67 mg/day at 
6 and 12 months, respectively. The average trough
level for the TAC group was 3.29 ± 1.58 ng/mL at
Tacrolimus and sirolimus in renal transplantation
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Table. The demographic characteristics and 12-month outcome of patients on tacrolimus + sirolimus + steroids
(TAC group) and those on cyclosporine + sirolimus + steroids (CsA group)
Characteristics and outcome TAC group (n = 21) CsA group (n = 20) p*
R-age (yr) 42.7 ± 2.3 40.2 ± 2.4 0.46
R-gender (M:F) 5:16 7:13 0.43
R-weight (kg) 55.1 ± 2.5 55.6 ± 2.5 0.88
Donor type (C:L) 13:8 13:7 0.84
D-age (yr) 46.5 ± 3.3 45.4 ± 3.3 0.82
D-sCre (mg/dL) 1.27 ± 0.13 1.22 ± 0.13 0.76
HLA mismatches 3.3 ± 0.3 2.8 ± 0.3 0.23
Delayed function 14.3% (3/21) 20.0% (4/20) 0.63
Biopsy-proven acute rejection 4.76% (1/21) 5% (1/20) 0.96
Graft loss 0 10% (2/20) 0.14
Patient death 0 0 –
Biopsy-proven CNI toxicity 4.76% (1/21) 10% (2/20) 0.61
CNI-switch 0 15% (3/20) 0.11
Wound complication 0 5% (1/20) 0.30
Infection 19.0% (4/21) 15% (3/20) 1.00
*Two-tailed t tests and Fisher’s exact tests were used for continuous variables and categorical variables, respectively, and log rank test
was used for acute rejection and graft loss. R = recipient; D = donor; C = cadaveric donor; L = live donor; HLA = human lymphocyte
antigen; CNI = calcineurin inhibitor.
6 months and 4.24 ± 1.23 ng/mL at 12 months.
The average daily doses for the CsA group were
1.57 ± 0.86 mg/day and 2.00 ± 0.82 mg/day at 6
and 12 months, respectively. The average trough
level for the CsA group was 5.19 ± 2.86 ng/mL at
6 months and 5.09 ± 1.75 ng/mL at 12 months.
The dose and trough level of sirolimus are sum-
marized in Figure 2. Sirolimus was discontinued
in four patients in the TAC group and in two pa-
tients in the CsA group. The reasons for stopping
sirolimus therapy included urine leakage from the
percutaneous cystostomy in two patients, elevation
of liver enzymes (1 patient), fever of unknown
origin (1 patient), hemolytic uremic syndrome
(1 patient) and deep vein thrombosis of the lower
limbs (1 patient).
After transplantation, the average eGFR was
52.77 ± 3.86 mL per minute for the TAC group at
6 months, and 46.42 ± 3.95 mL per minute for
the CsA group (p > 0.05). At 12 months, the aver-
age eGFR was 52.04 ± 4.38 mL per minute for the
TAC group, and 46.79 ± 4.38 mL per minute for
the CsA group (p > 0.05; Figure 3). In each group,
one biopsy-proven acute rejection episode (Banff
IA) developed and responded to steroid pulse
therapy. Toxicity of CNIs was noted in the biopsy
specimens in two patients, one in each group.
The 12-month acute rejection rate was 4.76% 
for the TAC group, and 5% for the CsA group.
Two patients in the CsA group lost their grafts at
12 months. The causes of graft loss were wound
disruption with graft incarceration in one patient
K.H. Chen, et al
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Figure 1. Mean doses (± SD) and trough levels (± SD) of: (A) cyclosporine (CsA) in patients in the CsA group; 
(B) tacrolimus (TAC) in patients in the TAC group.
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Figure 2. (A) Mean doses (± SD) of sirolimus (SRL) in patients in the CsA and TAC groups. (B) Mean trough levels (± SD)
of SRL in patients in the CsA and TAC groups.
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and progressive focal sclerosing glomerulonephri-
tis in the other. There was no wound complication
in the TAC group. The 12-month graft survival
rates were 90% for the CsA group and 100% for
the TAC group, and the 12-month patient survival
rates were 100% for both groups.
Post-transplant diabetes mellitus developed in
one patient in each group. Both required insulin
injection for control of blood sugar. Three pa-
tients in the TAC group and two in the CsA group
needed statins because of hypercholesterolemia.
One patient in each group took fibrates for hy-
perlipidemia. The lipid profiles of the two groups
are summarized in Figure 4. Four patients in the
TAC group developed infections, which included
peritoneal dialysis-related peritonitis (1 patient),
legionella pneumonia (1 patient), urinary tract
infection (1 patient) and fever of unknown origin
(1 patient). The infections in the CsA group were
quite similar to those in the TAC group, including
bacterial pneumonia (1 patient), urinary tract in-
fection (1 patient) and fever of unknown origin
(1 patient).
Discussion
Sirolimus has been recognized as a potent im-
munosuppressive agent with a different adverse
event profile from cyclosporine. In early phases
of clinical trials, de novo sirolimus therapy achieved
comparable results with cyclosporine in terms of
acute rejection and graft survival but produced
considerable dyslipidemia in the renal transplant
recipients.7 When combined with cyclosporine,
sirolimus could significantly reduce the incidence
of acute rejection, though sirolimus exacerbated
cyclosporine-related nephrotoxicity by a pharma-
cokinetic interaction.2,3 Therefore, it was cyclo-
sporine and the pharmacokinetic interaction with
sirolimus that jeopardized the graft renal function
of patients on combined sirolimus and cyclospor-
ine therapy.8 While tacrolimus has been shown
to interact less significantly with sirolimus, we
demonstrated that tacrolimus could be used in
combination with sirolimus for de novo renal trans-
plantation. Large-scale clinical trials will be needed
to address the issue of which CNI, cyclosporine
Tacrolimus and sirolimus in renal transplantation
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Figure 3. Mean estimated glomerular filtration rates (eGFR)
(± SD), as estimated by the Cockcroft-Gault formula, of 
patients in the CsA and TAC groups.
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Figure 4. (A) Mean triglyceride (TG) levels (± SD) of patients in the CsA and TAC groups. (B) Mean cholesterol levels
(± SD) of patients in the CsA and TAC groups.
or tacrolimus, provides better renal function and
graft survival for renal transplant patients.
The role of sirolimus in the immunosuppres-
sive management of kidney transplantation has
varied from a supplement to CNI-based regimens,
a replacement for antimetabolites in low-dose
CNI-based regimens or the main immunosup-
pressive agent in CNI-free regimens.9,10 In a large
multicenter randomized trial using different doses
of sirolimus, Vitko et al concluded that a fixed dose
of 2 mg sirolimus resulted in a low incidence of
acute rejection despite more cases of hyperlipi-
demia.11 In another prospective randomized trial
of tacrolimus combined with sirolimus or my-
cophenolate mofetil, Mendez et al found excellent
results in both arms with low acute rejection at 
6 months (11.4% and 13%, respectively).12 There
was no difference in graft survival but more ad-
verse effects occurred in the tacrolimus + sirolimus
group.12 In our study, we demonstrated that the
12-month acute rejection rate could be reduced
to around 5% when sirolimus was combined
with either cyclosporine or tacrolimus. There-
fore, with the introduction of sirolimus, the acute
rejection rate after kidney transplantation has
been dramatically reduced. We propose that
CNIs and sirolimus are actually working syner-
gistically; CNIs suppress T-cell activation and
sirolimus inhibits proliferation. This could be
the reason why such a low rejection rate could be
achieved with two immunosuppressive agents at
low doses.
Sirolimus, especially at high blood levels, was
found to produce significant side effects, includ-
ing poor wound healing, hyperlipidemia and
myelosuppression.7,13 Lymphocele, wound infec-
tion and incisional hernia were reported once 
in up to 47% of patients.14 Tacrolimus has been
demonstrated to increase the blood levels of
sirolimus far less than cyclosporine, and sirolimus
when combined with tacrolimus can have a syn-
ergistic effect in immunosuppression without the
side effects resulting from high sirolimus blood
levels. As demonstrated in our study, there were
no wound complications after sirolimus therapy
except for one patient in the CsA group, who was
obese and suffered from wound disruption. Mean-
while, the antiproliferative effect associated with
sirolimus is a unique characteristic with potential
benefit to patients under immunosuppression.
Kauffman et al concluded, in a multivariate analy-
sis of post-transplant malignancy, that a signifi-
cantly reduced risk of de novo malignancy was
noted in patients given sirolimus maintenance
therapy.15
Taking into account all the factors including
graft function, incidence of acute rejection, graft
and patient survival, infection and metabolic ad-
verse effects, low-dose tacrolimus combined with
de novo sirolimus therapy resulted in a favorable
outcome in this study: the graft renal function
was well preserved with little renal toxicity, and
the incidence of acute rejection was very low. 
The risk of infection was not high and the meta-
bolic side effects were manageable. A large-scale
randomized study will be necessary to demon-
strate the superiority of tacrolimus and sirolimus
combined therapy in Taiwanese renal transplant 
recipients.
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